BioNova - Mobilitet för biologiska läkemedel
|Coordinator||KUNGLIGA TEKNISKA HÖGSKOLAN - Institutionen för kemi|
|Funding from Vinnova||SEK 300 000|
|Project duration||September 2016 - December 2017|
|Venture||Personal mobility between societal sectors|
|Call||National mobility for individuals|
Purpose and goal
BioNova has established and strengthened collaboration between academia (Assoc. Prof. Syrén vid KTH) and the drug company Swedish Orphan Biovitrum (Sobi) AB within design and development of biopharmaceuticals. The industrial potential of the commonly acquired, and exchanged, knowledge in BioNova is currently under evaluation at Sobi. The novel perspectives from the mobility have been implemented in teaching at KTH within the scope of a project course for PhD-students.
Expected results and effects
The results from the project have already lead to development and implementation of a leading academic bioinformatical method in industry, to enable generation of tailor-made biopharmaceuticals. The effect and potential of this method will be evaluated in on-going projects at Sobi within lysosomal diseases. In the long term BioNova thus displays great potential to facilitate accelerated production of protein pharmaceuticals with improved properties.
Planned approach and implementation
The project was performed by close collaboration between the academic partner and a multidisciplinary project group in protein engineering at Sobi. Distribution of the project over the whole project period, rather than focusing over a shorter time frame, constituted an advantage and facilitated keeping project meetings and technology development in phase. The advancement of the project was significantly facilitated by the fact that Syrén’s research group and Sobi AB are localized in the same building at Science for Life Laboratory.